Gossamer Bio, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value amounts)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $41,148 | $37,732 |
| Marketable securities | 15,878 | 99,200 |
| Receivable from contracts with collaborators | 6,105 | 12,227 |
| Prepaid expenses and other current assets | 9,594 | 18,485 |
| Total current assets | 72,725 | 167,644 |
| Property and equipment, net | 55 | 64 |
| Operating lease right-of-use assets | 3,658 | 4,133 |
| Other assets | 429 | 408 |
| Total assets | $76,867 | $172,249 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $5,951 | $5,959 |
| Accrued research and development expenses | 9,680 | 21,662 |
| Current contract liabilities | 7,068 | 19,987 |
| Current convertible senior notes | 36,145 | — |
| Warrant liability at fair value | 18,291 | — |
| Embedded derivative liability at fair value | 42,938 | — |
| Accrued expenses and other current liabilities | 17,710 | 15,827 |
| Total current liabilities | 137,783 | 63,435 |
| Long-term convertible senior notes | — | 198,508 |
| Operating lease liabilities - long-term | 2,958 | 3,460 |
| Long-term contract liabilities | 30,155 | 29,606 |
| Total liabilities | 170,896 | 295,009 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity (deficit) | ||
| Common stock, $0.0001 par value; 700,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 488,846,723 shares issued and outstanding as of June 30, 2026, and 233,677,057 shares issued and outstanding as of December 31, 2025 | 50 | 24 |
| Additional paid-in capital | 1,378,357 | 1,321,303 |
| Accumulated deficit | (1,468,702) | (1,438,938) |
| Accumulated other comprehensive loss | (3,734) | (5,149) |
| Total stockholders' deficit | (94,029) | (122,760) |
| Total liabilities and stockholders' deficit | $76,867 | $172,249 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.